What is the ticker symbol for Acadia Pharmaceuticals?

Acadia Pharmaceuticals trades under the ticker ACAD on NASDAQ.

What sector does Acadia Pharmaceuticals operate in?

Acadia Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ACAD in a portfolio?

PortView shows ACAD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Acadia Pharmaceuticals (ACAD) Stock Analysis

NASDAQHealthcareBiotechnology

$20.25+0.40%

1-year price historyRange $18.62 – $30.57

52-week range$20.25

$18.39$30.96

Track ACAD in your portfolio for free · Portfolio tracker

What Acadia Pharmaceuticals does

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Key metrics

Market cap

$3.49B

P/E (TTM)

9.12

EPS (TTM)

$2.22

Beta

0.89

Dividend yield

0.00%

Revenue / share

$6.64

50-day avg

$24.30

200-day avg

$23.77

52-week high

$30.96

52-week low

$18.39

CEO

Catherine E. Owen Adams

ETFs linked to ACAD

Broad-market and Healthcare sector ETFs an investor holding Acadia Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how ACAD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ACAD in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Acadia Pharmaceuticals?: Acadia Pharmaceuticals trades under the ticker ACAD on NASDAQ.
Which exchange is ACAD listed on?: ACAD is listed on NASDAQ.
What sector does Acadia Pharmaceuticals operate in?: Acadia Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze ACAD in a portfolio?: PortView shows ACAD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.